Summary:
The purpose of this study is to assess the efficacy and safety of LY3314814 compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease.
Qualified Participants Must:
• Be between 55 and 85 years of age (Adult, Senior)
•
Have had gradual and progressive change in the participant's memory function over more than 6 months, reported by participant and study partner
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.